Abstract
There is growing evidence to support the use of botulinum toxin (BTX) in idiopathic detrusor overactivity. However, BTX remains off label for this purpose. In this commentary, we review the current status of the literature discussing the evidence for efficacy and safety of BTX. In addition, we present the data regarding the preparation, dose, and administration of BTX. As an emerging treatment, high-level evidence exists for the use of BTX in patients with idiopathic detrusor overactivity; however, details about the optimum number of injection sites and injection volume remain to be answered. In addition, long-term data regarding the effect of repeated injections requires further study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
